Company: LRHC
Filing Date: 2025-08-20
Form Type: S-1/A
Source: 0001213900-25-078966
Chunk: 44

Company: La Rosa Holdings Corp.
Filing Date: 2025-08-20
Form: S-1/A
Chunk 44
---
 obtained stockholder approval as required for issuance of common stock in excess
of the Exchange Cap, in accordance with the applicable rules of Nasdaq. Accordingly, the Company may not have access to the right to sell
the full Commitment Amount to the Selling Stockholder under the Facility until such stockholder approval is obtained.

Pursuant to the Facility Agreement, the Company
is required to provide each stockholder entitled to vote at a meeting of stockholders of the Company (the “Stockholder Meeting”),
which shall be promptly called and held not later than sixty (60) days after the Agreement Date (the “Stockholder Meeting Deadline”),
a proxy statement in a form reasonably acceptable to the Investor and counsel, at the expense of the Company to solicit each of the Company’s
stockholders’ affirmative vote at the Stockholder Meeting for approval of the proposal (“Stockholder Proposal”) to authorize
the issuance of all of the Advance Shares issuable thereunder in compliance with the rules and regulations of the Nasdaq Capital Market
(such affirmative approval being referred to herein as the “Stockholder Approval”, and the date such Stockholder Approval
is obtained, the “Stockholder Approval Date”), and the Company is required to use its reasonable best efforts to solicit its
stockholders’ approval of such proposal and to cause the board of directors of the Company to recommend to the stockholders that
they approve such proposal.

Notwithstanding the foregoing, if the Company
is able to obtain the written consent of holders of a majority of the shares of its issued and outstanding Advance Shares to obtain Stockholder
Approval (the “Stockholder Consent”), the Company may satisfy the foregoing obligations under the EPFA by obtaining such consent
and submitting for filing with the Securities and Exchange Commission a Preliminary Information Statement on Schedule 14C no later than
20 days prior to the Stockholder Meeting Deadline, followed by a Definitive Information Statement on Schedule 14C no later than the timeline
for such filing prescribed by the Securities Exchange Act of 1934, as amended; provided, however, that if the Company receives a notification
from the Nasdaq Capital Market that the Stockholder Consent must be modified, then the Company shall use its best efforts to provide a
new Stockholder Consent.

There are substantial risks to the Company’s
stockholders as a result of the sale and issuance of Advance Shares to the Selling Stockholder under the Facility Agreement. These risks include the potential
for substantial dilution and significant declines in the share price of the Company’s